Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 4Phase 1 4Phase NA 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 1

Conditions

Adenocarcinoma 4Stomach Neoplasms 3Neoplasms 3Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Interventional × zolbetuximab × Clear all
NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03504397 2026-05-04

Spotlight

Astellas Pharma Inc

Phase 3 Active not recruiting
565 enrolled 63 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT06901531 2026-04-29

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT03653507 2026-04-17

GLOW

Astellas Pharma Inc

Phase 3 Active not recruiting
507 enrolled 65 charts 1 FDA
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡